Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Eukaryotic initiation factor 5B (eIF5B) regulates temozolomide-mediated apoptosis in brain tumor stem cells (BTSCs).

Ross JA, Ahn BY, King J, Bressler KR, Senger DL, Thakor N.

Biochem Cell Biol. 2019 Oct 31. doi: 10.1139/bcb-2019-0329. [Epub ahead of print]

PMID:
31671279
2.

Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.

Shen Y, Grisdale CJ, Islam SA, Bose P, Lever J, Zhao EY, Grinshtein N, Ma Y, Mungall AJ, Moore RA, Lun X, Senger DL, Robbins SM, Wang AY, MacIsaac JL, Kobor MS, Luchman HA, Weiss S, Chan JA, Blough MD, Kaplan DR, Cairncross JG, Marra MA, Jones SJM.

Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19098-19108. doi: 10.1073/pnas.1813495116. Epub 2019 Aug 30.

PMID:
31471491
3.

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver.

Choudhury SR, Babes L, Rahn JJ, Ahn BY, Goring KR, King JC, Lau A, Petri B, Hao X, Chojnacki AK, Thanabalasuriar A, McAvoy EF, Tabariès S, Schraeder C, Patel KD, Siegel PM, Kopciuk KA, Schriemer DC, Muruve DA, Kelly MM, Yipp BG, Kubes P, Robbins SM, Senger DL.

Cell. 2019 Aug 22;178(5):1205-1221.e17. doi: 10.1016/j.cell.2019.07.017.

PMID:
31442408
4.

Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma.

Hoffman M, Gillmor AH, Kunz DJ, Johnston MJ, Nikolic A, Narta K, Zarrei M, King J, Ellestad K, Dang NH, Cavalli FMG, Kushida MM, Coutinho FJ, Zhu Y, Luu B, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Pugh TJ, Dirks PB, Strother D, Lafay-Cousin L, Resnick AC, Scherer S, Senger DL, Simons BD, Chan JA, Morrissy AS, Gallo M.

Cancer Res. 2019 May 1;79(9):2111-2123. doi: 10.1158/0008-5472.CAN-18-3441. Epub 2019 Mar 15.

PMID:
30877103
5.

A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth.

Goh ETH, Lin Z, Ahn BY, Lopes-Rodrigues V, Dang NH, Salim S, Berger B, Dymock B, Senger DL, Ibáñez CF.

Cell Chem Biol. 2018 Dec 20;25(12):1485-1494.e5. doi: 10.1016/j.chembiol.2018.09.007. Epub 2018 Oct 4.

PMID:
30293939
6.

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.

Yuan AL, Ricks CB, Bohm AK, Lun X, Maxwell L, Safdar S, Bukhari S, Gerber A, Sayeed W, Bering EA, Pedersen H, Chan JA, Shen Y, Marra M, Kaplan DR, Mason W, Goodman LD, Ezhilarasan R, Kaufmann AB, Cabral M, Robbins SM, Senger DL, Cahill DP, Sulman EP, Cairncross JG, Blough MD.

PLoS One. 2018 Aug 28;13(8):e0202860. doi: 10.1371/journal.pone.0202860. eCollection 2018.

7.

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2018 Jul 18;9:16231. doi: 10.1038/ncomms16231.

8.

Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury.

Lau A, Chung H, Komada T, Platnich JM, Sandall CF, Choudhury SR, Chun J, Naumenko V, Surewaard BG, Nelson MC, Ulke-Lemée A, Beck PL, Benediktsson H, Jevnikar AM, Snelgrove SL, Hickey MJ, Senger DL, James MT, Macdonald JA, Kubes P, Jenne CN, Muruve DA.

J Clin Invest. 2018 Jul 2;128(7):2894-2913. doi: 10.1172/JCI96640. Epub 2018 Jun 4.

9.

Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells.

Sarkar S, Mirzaei R, Zemp FJ, Wei W, Senger DL, Robbins SM, Yong VW.

Cancer Res. 2017 Jun 15;77(12):3231-3243. doi: 10.1158/0008-5472.CAN-16-2171. Epub 2017 Apr 17.

10.

The Role of Neurotrophin Signaling in Gliomagenesis: A Focus on the p75 Neurotrophin Receptor (p75NTR/CD271).

Alshehri MM, Robbins SM, Senger DL.

Vitam Horm. 2017;104:367-404. doi: 10.1016/bs.vh.2016.11.001. Epub 2017 Jan 4. Review.

PMID:
28215302
11.

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2017 Feb 15;8. doi: 10.1038/ncomms14278. Erratum in: Nat Commun. 2018 Jul 18;9:16231.

12.

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells.

Corredor JC, Redding N, Bloté K, Robbins SM, Senger DL, Bell JC, Beaudry P.

Mol Ther Oncolytics. 2016 Mar 16;3:16005. doi: 10.1038/mto.2016.5. eCollection 2016.

13.

Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.

Grinshtein N, Rioseco CC, Marcellus R, Uehling D, Aman A, Lun X, Muto O, Podmore L, Lever J, Shen Y, Blough MD, Cairncross GJ, Robbins SM, Jones SJ, Marra MA, Al-Awar R, Senger DL, Kaplan DR.

Oncotarget. 2016 Sep 13;7(37):59360-59376. doi: 10.18632/oncotarget.10661.

14.

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.

Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, Wrana JL, Easaw JC, Luchman A, Weiss S, Cairncross JG, Kaplan DR, Robbins SM, Senger DL.

Clin Cancer Res. 2016 Aug 1;22(15):3860-75. doi: 10.1158/1078-0432.CCR-15-1798. Epub 2016 Mar 22.

15.

QuantitativeT2: interactive quantitative T2 MRI witnessed in mouse glioblastoma.

Ali TS, Bjarnason TA, Senger DL, Dunn JF, Joseph JT, Mitchell JR.

J Med Imaging (Bellingham). 2015 Jul;2(3):036002. doi: 10.1117/1.JMI.2.3.036002. Epub 2015 Jul 21.

16.

Glioma invasion mediated by the p75 neurotrophin receptor (p75(NTR)/CD271) requires regulated interaction with PDLIM1.

Ahn BY, Saldanha-Gama RF, Rahn JJ, Hao X, Zhang J, Dang NH, Alshehri M, Robbins SM, Senger DL.

Oncogene. 2016 Mar 17;35(11):1411-22. doi: 10.1038/onc.2015.199. Epub 2015 Jun 29.

17.

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Sep 15;20(18):4894-903. doi: 10.1158/1078-0432.CCR-13-1856. Epub 2014 Jul 30.

18.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

19.

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA.

Mol Ther. 2010 Nov;18(11):1927-36. doi: 10.1038/mt.2010.183. Epub 2010 Aug 31.

20.

Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2010 Jan 15;70(2):598-608. doi: 10.1158/0008-5472.CAN-09-1510. Epub 2010 Jan 12.

21.

Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.

Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL, Forsyth P, Auer RN, Dunn JF, Cairncross JG, Parney IF, Weiss S.

Stem Cells. 2009 Aug;27(8):1722-33. doi: 10.1002/stem.98.

22.

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.

Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342. Epub 2009 Apr 7.

23.

Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor.

Wang L, Rahn JJ, Lun X, Sun B, Kelly JJ, Weiss S, Robbins SM, Forsyth PA, Senger DL.

PLoS Biol. 2008 Nov 25;6(11):e289. doi: 10.1371/journal.pbio.0060289.

24.

Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Wu Y, Lun X, Zhou H, Wang L, Sun B, Bell JC, Barrett JW, McFadden G, Biegel JA, Senger DL, Forsyth PA.

Clin Cancer Res. 2008 Feb 15;14(4):1218-27. doi: 10.1158/1078-0432.CCR-07-1330.

25.

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2007 Sep 15;67(18):8818-27.

26.

The p75 neurotrophin receptor is a central regulator of glioma invasion.

Johnston AL, Lun X, Rahn JJ, Liacini A, Wang L, Hamilton MG, Parney IF, Hempstead BL, Robbins SM, Forsyth PA, Senger DL.

PLoS Biol. 2007 Aug;5(8):e212.

27.

Proteolytic disassembly is a critical determinant for reovirus oncolysis.

Alain T, Kim TS, Lun X, Liacini A, Schiff LA, Senger DL, Forsyth PA.

Mol Ther. 2007 Aug;15(8):1512-21. Epub 2007 May 22.

28.

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.

J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57.

PMID:
17077357
29.

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, Forsyth PA.

Cancer Res. 2005 Nov 1;65(21):9982-9990. doi: 10.1158/0008-5472.CAN-05-1201.

30.

Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.

Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ, Dyck R, Coffey M, Thompson B, Hamilton M, Nishikawa SG, Brasher PM, Fonseca K, George D, Rewcastle NB, Johnston RN, Stewart D, Lee PW, Senger DL, Forsyth PA.

Clin Cancer Res. 2004 Dec 15;10(24):8561-76.

31.

Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.

Yang WQ, Senger DL, Lun XQ, Muzik H, Shi ZQ, Dyck RH, Norman K, Brasher PM, Rewcastle NB, George D, Stewart D, Lee PW, Forsyth PA.

Gene Ther. 2004 Nov;11(21):1579-89.

PMID:
15372068
32.

Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors.

Vieyra D, Senger DL, Toyama T, Muzik H, Brasher PM, Johnston RN, Riabowol K, Forsyth PA.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5952-61. Erratum in: Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4198. Clin Cancer Res. 2004 May 1;10(9):3233. Toyam, Tatsuya [corrected to Toyama, Tatsuya].

33.

Spatial requirements for TrkA kinase activity in the support of neuronal survival and axon growth in rat sympathetic neurons.

MacInnis BL, Senger DL, Campenot RB.

Neuropharmacology. 2003 Dec;45(7):995-1010.

PMID:
14573392
34.

Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes.

Senger DL, Tudan C, Guiot MC, Mazzoni IE, Molenkamp G, LeBlanc R, Antel J, Olivier A, Snipes GJ, Kaplan DR.

Cancer Res. 2002 Apr 1;62(7):2131-40.

36.

Spatial regulation of neuronal gene expression in response to nerve growth factor.

Toma JG, Rogers D, Senger DL, Campenot RB, Miller FD.

Dev Biol. 1997 Apr 1;184(1):1-9.

37.
38.
39.

The response of plasma fibronectin to acute myocardial infarction in humans.

Dyck RF, Orchard RC, Senger DL.

Clin Invest Med. 1990 Jun;13(3):107-10.

PMID:
2114244

Supplemental Content

Loading ...
Support Center